Mesoblast Ltd (ASX:MSB), a regenerative medicine company, at 2020 International Society for Cell & Gene Therapy Annual meeting, announced that treatment with its lead mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with chronic obstructive pulmonary disease (COPD) and a high state of inflammation resulted in better respiratory and functional results. Key findings included:
- The greater the degree of inflammation, the greater the signal of efficacy of remestemcel-L treatment
- Considerable improvements in each of the pre-specified endpoints tested
- Six-minute walk test is a major independent predictor of mortality in COPD
- The dose processed was well tolerated with no infusion-related toxicity and no identified safety concerns
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.